Fig. 7.
BT-Br reduces DU145 prostate cancer tumors effectively in vivo. (A) Tumor growth inhibition by BT-Br intraperitoneal injection at 70% PEG400 (Vehicle), 10 and 20 mpk (daily), or CDDP at 6 mpk (weekly). (B) The inhibition rate of tumor volume (IRTV) analysis of BT-Br and CDDP corresponding to the data of a. IRTV (%) = 100 × (CTV-TTV)/CTV. CTV: the tumor volume of vehicle group; TTV: the tumor volume of treatment group. Tumor volumes (C) and body weight (D) analyses, at 1, 4, 6, 8, 11, 13, 15 days post-injection in male Balb/c Nude mice injected with DU145 cells, in Vehicle, BT-Br and CDDP groups, respectively. The analysis of tumor endpoint weight (E) and the tumor endpoint photo (F) at 15 days post-injection in mice upon treatment with 70% PEG400, BT- Br and CDDP, respectively. Error bars represent means ± SEM (n = 5 per group); Fig. 7a: two-way ANOVA followed by Bonferroni post hoc test; Fig. 7c,d,e: two-tailed unpaired t-test. *p < 0.05, **p < 0.01, or ****p < 0.0001, ns, not significant.